Equities

Kobayashi Pharmaceutical Co Ltd

Kobayashi Pharmaceutical Co Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (JPY)5,543.00
  • Today's Change-37.00 / -0.66%
  • Shares traded990.60k
  • 1 Year change-35.09%
  • Beta0.1841
Data delayed at least 20 minutes, as of Apr 26 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.

  • Revenue in JPY (TTM)173.46bn
  • Net income in JPY20.34bn
  • Incorporated1919
  • Employees3.53k
  • Location
    Kobayashi Pharmaceutical Co LtdKDX Kobayashi Doshomachi Bldg.4-4-10, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
  • Phone+81 662311144
  • Websitehttps://www.kobayashi.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4967:TYO since
announced
Transaction
value
Focus Consumer Healthcare LLCDeal completed05 Oct 202305 Oct 2023Deal completed-18.33%75.00m
Data delayed at least 20 minutes, as of Apr 26 2024 07:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Piramal Enterprises Ltd151.85bn-38.28bn392.88bn12.22k------2.59-90.77-90.77339.88--------6,545,270.00--3.41--4.5147.2988.04-25.2126.30--0.2287--22.746.82-4.74528.3114.25-24.794.90
Dizal Jiangsu Pharmaceutical Co Ltd876.29m-23.05bn403.18bn328.00--16.74--460.09-2.59-2.590.09842.650.0204--1.52122,263.40-53.53---66.24--93.97---2,630.41--2.02--0.202---100.00---9.87------
Lotus Pharmaceutical Co Ltd82.34bn19.94bn404.63bn1.10k20.074.8015.674.9115.6715.6764.6965.540.54252.133.07--13.139.1715.7611.3655.3449.3224.2115.991.96--0.400626.7715.8921.4135.91110.4452.35--
Chongqing Taiji Industry Group Co Ltd341.38bn17.96bn424.94bn12.59k23.655.37--1.241.481.4828.056.501.073.327.831,240,976.005.820.781418.622.3547.3944.035.460.84980.51476.180.565825.7610.587.88131.9963.553.8624.57
Kobayashi Pharmaceutical Co Ltd173.46bn20.34bn432.63bn3.53k20.672.0116.392.49268.11268.112,287.062,755.170.66293.883.4449,081,780.007.778.019.7910.1855.5656.4511.7312.242.43--0.004833.194.330.70371.582.4529.678.88
China Traditional Chinese Med Hldg CoLtd396.34bn28.11bn437.99bn17.30k15.580.94648.011.110.27590.27593.894.540.49861.472.091,132,450.003.844.605.857.0751.1857.077.709.771.488.010.1773--26.699.9968.11-2.24----
Laurus Labs Ltd95.70bn3.05bn447.10bn5.75k147.125.7342.604.672.972.9793.2776.270.62821.383.11--2.1010.133.2116.4751.7549.353.3412.830.63932.150.3851---16.5517.07-79.6811.3621.6821.67
Tonghua Dongbao Pharmaceutical Co Ltd67.20bn25.52bn461.34bn3.20k18.062.93--6.860.58630.58631.543.620.42360.92235.06962,270.4016.0918.6816.8919.6879.6278.7337.9839.204.06--0.020441.7310.692.69-26.176.85-14.754.56
Nanjing King-Frind Bchmcl Phrmctcl C Ltd87.49bn22.36bn467.72bn1.40k20.863.13--5.350.63460.63462.484.230.38130.36924.832,867,937.009.7212.9314.4918.9649.0053.8725.5027.461.02--0.32420.300.70627.252.9828.2642.1023.27
PharmaEssentia Corp24.79bn-3.03bn472.48bn131.00--3.95--19.06-2.05-2.0516.2072.270.23970.47694.84---2.93-16.79-3.29-19.6688.0476.47-12.22-79.569.96--0.0477--77.15186.9754.62--66.34--
Genscript Biotech Corp132.92bn-15.12bn473.45bn6.94k--2.15--3.56-0.3548-0.35483.125.130.2837.595.45947,323.20-11.97-18.34-18.27-26.1548.7854.68-42.30-64.914.65--0.1694--34.1729.4457.91--17.14--
Data as of Apr 26 2024. Currency figures normalised to Kobayashi Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

11.89%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 Apr 20242.08m2.66%
Nomura Asset Management Co., Ltd.as of 29 Mar 20241.95m2.50%
Norges Bank Investment Managementas of 31 Dec 2023981.24k1.26%
Nikko Asset Management Co., Ltd.as of 05 Apr 2024889.40k1.14%
Daiwa Asset Management Co. Ltd.as of 29 Mar 2024865.00k1.11%
Comgest SAas of 30 Jun 2023734.90k0.94%
BlackRock Fund Advisorsas of 04 Apr 2024581.00k0.74%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Apr 2024447.90k0.57%
Fidelity Management & Research Co. LLCas of 29 Feb 2024398.55k0.51%
MFS International Singapore Pte. Ltd.as of 29 Feb 2024348.70k0.45%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.